Anavex Life Sciences Corp. Common Stock (AVXL)
Stock · NASDAQ · Health Care
$2.98as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$2.65
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 34
- Website
- www.anavex.com
Fundamentals
- 1-day range
- $3.32$3.4
- Market cap
- $303.96M
- P/E (trailing)
- —
- P/E (forward)
- -6.07
- EPS (trailing)
- $-0.46
- Dividend yield
- —
- Beta
- 1.16
- Avg. volume
- 1.25M
52-week range
$2.26$10.4
Next earnings: August 10, 2026 · EPS estimate $-0.08After Closeconfirmed
Forecasts
1 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$20
+571.1%
Median
$20
+571.1%
Low
$20
+571.1%
Anavex Life Sciences Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- AVXLAnavex Life Sciences Corp. Common Stock$2.98▼ 4.79%Market cap $303.96MP/E —$2.26$10.4
- NMRANeumora Therapeutics Inc. Common Stock$1.38▼ 6.76%Market cap $303.87MP/E —$0.83015$3.65
- SABSSAB Biotherapeutics Inc. Common Stock$3.79▼ 3.56%Market cap $294.39MP/E 26.94$1.85$5.15
- FATEFate Therapeutics Inc. Common Stock$2.42▼ 4.92%Market cap $290.23MP/E —$0.93$3.23
- IKTInhibikase Therapeutics Inc. Common Stock$2.42▼ 2.23%Market cap $318.20MP/E —$1.33$2.54
- EDITEditas Medicine Inc. Common Stock$3.15▼ 4.55%Market cap $283.93MP/E —$1.66$4.54
- LCTXLineage Cell Therapeutics Inc. Common Stock$1.11▼ 4.31%Market cap $281.71MP/E —$1$2.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $2.98 | ▼ 4.79% | $2.26$10.4 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $1.38 | ▼ 6.76% | $0.83015$3.65 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 26.94 | $3.79 | ▼ 3.56% | $1.85$5.15 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $2.42 | ▼ 4.92% | $0.93$3.23 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $2.42 | ▼ 2.23% | $1.33$2.54 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $3.15 | ▼ 4.55% | $1.66$4.54 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $1.11 | ▼ 4.31% | $1$2.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Anavex: After The EU Said No, The FDA Path Looks Long And ExpensiveSeekingAlpha · 8/26/2026
- Let's uncover which stocks are experiencing notable gaps during today's session.ChartMill · 8/25/2026
- Anavex Life Sciences Q3 EPS $0.08 Beats $(0.08) Estimatebenzinga · 8/25/2026
- Anavex Life Sciences Q3 EPS $0.08 Beats $(0.08) EstimateBenzinga · 8/25/2026
- Anavex Life Sciences Urges Stockholders To Reject Attempt By PVG Asset Management And Patrick S. Adams To Acquire Control Of The CompanyBenzinga · 8/3/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 40.36M
- Total value held
- $121.08M
- Institutional holders
- 187
Top holders this quarter
- Unknown7.61M
- Unknown4.51M
- Unknown3.86M
- Unknown3.25M
- Unknown2.19M
- Unknown1.54M
- Unknown1.17M
- Unknown940.5K
- Unknown863.1K
- Unknown804.4K
See the full, filterable feed with live charts on the MarketWall dashboard.